




Figure S2. Determination of COX1, mPGES-2 and cPGES protein levels following astrocyte treatment with various inhibitors or knockdown of CD74 expression. **(a)** Western blot analysis of COX1, mPGES-2 and cPGES following astrocytes stimulation with 1 μ g/ml recombinant D-DT in the presence or absence of 100 μ M selective inhibitor 4-CPPC for 24 h. Quantities were normalized to endogenous β -actin as shown in Fig. 5a. **(b)** Western blot analysis of COX1, mPGES-2 and cPGES following astrocyte treatment with 1 μ g/ml recombinant D-DT in the presence

or absence of 30 μ M NS398 for 24 h. Quantities were normalized to endogenous β -actin as shown in Fig. 6a. **(c)** Western blot analysis of mPGES-2 and cPGES following siRNA2 knockdown of CD74 receptor for 48 h, prior to stimulation with 1 μ g/ml recombinant D-DT protein for 24 h. Quantities were normalized to endogenous β -actin as shown in Fig. 7c. **(d)** Western blot analysis of COX1, mPGES-2 and cPGES following treatment with 1 μ g/ml recombinant D-DT in the presence of 10 μ M P38 (SB203580), 10 μ M JNK (SP600125), or 10 μ M ERK (PD98059) inhibitor for 24 h. Quantities were normalized to endogenous β -actin as shown in Fig. 8a. **(e)** Western blot analysis of COX1, mPGES-2 and cPGES following astrocyte co-stimulation with 1 μ g/ml recombinant MIF and/or equivalent D-DT in the presence or absence of 100 μ M 4-IPP or 4-CPPC for 24 h. Quantities were normalized to endogenous β -actin (for COXs or PGE synthase) as shown in Fig. 9a. Experiments were performed in triplicates. Error bars represent the standard deviation (*P < 0.05).